NDATOPICALOINTMENT
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
ULTRAVATE (halobetasol propionate) by PharmaIN is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown. Approved for psoriasis. First approved in 1990.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULTRAVATE (halobetasol propionate) is a potent topical corticosteroid ointment approved in 1990 for the treatment of plaque psoriasis. It works through signaling, immune function, inflammation, and protein regulation, though its precise mechanism in psoriasis remains incompletely understood. This is a small-molecule topical therapeutic indicated for inflammatory skin conditions.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling need for defensive strategies and potential team reductions in commercial roles.
Mechanism of Action
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown.
Indications (1)
Clinical Trials (2)
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis
Started Apr 2016
154 enrolled
Psoriasis
Career Relevance
Worked on ULTRAVATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.